Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease
- PMID: 25989816
- PMCID: PMC9507283
- DOI: 10.1017/S0950268815000837
Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease
Abstract
We studied the epidemiology and microbiology of Clostridium difficile and the characteristics of patients with C. difficile infection (CDI) in Crete in three groups of hospitalized patients with diarrhoea: group 1 [positive culture and positive toxin by enzyme immunoassay (EIA)]; group 2 (positive culture, negative toxin); group 3 (negative culture, negative toxin). Patients in group 1 were designated as those with definitive CDI (20 patients for whom data was available) and matched with cases in group 2 (40 patients) and group 3 (40 patients). C. difficile grew from 6% (263/4379) of stool specimens; 14·4% of these had positive EIA, of which 3% were resistant to metronidazole. Three isolates had decreased vancomycin susceptibility. Patients in groups 1 and 2 received more antibiotics (P = 0·03) and had more infectious episodes (P = 0·03) than patients in group 3 prior to diarrhoea. Antibiotic administration for C. difficile did not differ between groups 1 and 2. Mortality was similar in all three groups (10%, 12·5% and 5%, P = 0·49). CDI frequency was low in the University Hospital of Crete and isolates were susceptible to metronidazole and vancomycin.
Keywords: C. difficile mortality; C. difficile resistance; C. difficile susceptibility; C. difficile toxin; C. difficile-associated diarrhoea.
Conflict of interest statement
None.
Figures
Similar articles
-
Clostridioides (Clostridium) difficile in adults with diarrhoea in Vietnam.Anaerobe. 2023 Jun;81:102741. doi: 10.1016/j.anaerobe.2023.102741. Epub 2023 May 25. Anaerobe. 2023. PMID: 37244476
-
Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.Microbiol Spectr. 2021 Oct 31;9(2):e0079921. doi: 10.1128/Spectrum.00799-21. Epub 2021 Oct 20. Microbiol Spectr. 2021. PMID: 34668727 Free PMC article.
-
Epidemiology of Clostridioides difficile PCR ribotype 181 after the COVID-19 pandemic in Northern Greece.Acta Microbiol Immunol Hung. 2024 Oct 28;71(4):315-323. doi: 10.1556/030.2024.02401. Print 2024 Dec 19. Acta Microbiol Immunol Hung. 2024. PMID: 39466344
-
Ridinilazole: a novel therapy for Clostridium difficile infection.Int J Antimicrob Agents. 2016 Aug;48(2):137-43. doi: 10.1016/j.ijantimicag.2016.04.026. Epub 2016 May 30. Int J Antimicrob Agents. 2016. PMID: 27283730 Review.
-
Clostridioides difficile Infection: Diagnosis and Treatment Challenges.Pathogens. 2024 Jan 27;13(2):118. doi: 10.3390/pathogens13020118. Pathogens. 2024. PMID: 38392856 Free PMC article. Review.
Cited by
-
Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158. doi: 10.1186/s13756-020-00815-5. Antimicrob Resist Infect Control. 2020. PMID: 32977835 Free PMC article.
-
The Incidence of Clostridioides difficile Infection in the Post-COVID-19 Era in a Hospital in Northern Greece.Diseases. 2024 Aug 20;12(8):190. doi: 10.3390/diseases12080190. Diseases. 2024. PMID: 39195189 Free PMC article.
References
-
- CDC. Antibiotic resistance threats in the United States, 2013.
-
- Bignardi GE. Risk factors for Clostridium difficile infection. Journal of Hospital Infection 1998; 40: 1–15. - PubMed
-
- Wistrom J, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. Journal of Antimicrobial Chemotherapy 2001; 47: 43–50. - PubMed
-
- Aronsson B, Mollby R, Nord CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980–1982. Journal of Infectious Diseases 1985; 151: 476–481. - PubMed
-
- McFarland LV, et al. Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 1989; 320: 204–210. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical